Loading
Founded the German Breast Group and led KATHERINE, which made T-DM1 standard after residual disease.
Gunter von Minckwitz is the founder and former Chair of the German Breast Group (GBG). His specialisms are breast cancer, neoadjuvant chemotherapy and residual disease. He led the GeparTrio and GeparQuinto neoadjuvant trials and was principal investigator of KATHERINE, the trial of adjuvant trastuzumab emtansine for patients with residual invasive HER2-positive breast cancer after neoadjuvant therapy, reported in the New England Journal of Medicine. KATHERINE made T-DM1 the standard after residual disease. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE) | NEJM | 2019 |
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
The survival evidence behind platinum in early triple-negative disease, and the first large demonstration that most triple-negative tumours are DNA-repair deficient whether or not BRCA is mutated, which is why HRD scores have not become a platinum selection test.
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, HER2-positive breast cancer.
Shares Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto, GeparSixto, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto, German Breast Group (GBG), KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares KATHERINE, German Breast Group (GBG), Trastuzumab emtansine, HER2-positive breast cancer.
Shares Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto, German Breast Group (GBG).